
 Scientific claim: aPKCz causes tumour suppression by affecting glutamine metabolism. 
 Participant Dynamics: Advocate vs. Skeptic 
 Contextual Arena: The Didactic Arena (goal: to teach or learn) 
 Interaction Trigger: A Point of Confusion (a misunderstanding or contradiction) 
 Dialogue Objective: To Define the Disagreement (map out points of conflict) 
```
Advocate: Alright, let's dive into this. The assertion is that aPKCz causes tumour suppression by affecting glutamine metabolism. It's quite a revolutionary idea, don't you think?

Skeptic: It is indeed interesting. However, I can't help but question the mechanism. How exactly does altering glutamine metabolism lead to tumour suppression?

Advocate: Ah, that's the beauty of it. aPKCz modulates the activity of glutamine transporters, effectively starving the tumour cells. Without sufficient glutamine, their growth is inhibited.

Skeptic: But don't cancer cells typically adapt quickly to metabolic changes? What's stopping them from finding an alternative nutrient source?

Advocate: Good point. While cancer cells are adaptable, aPKCz's role is unique. It not only affects glutamine uptake but also disrupts the signaling pathways that would enable adaptation.

Skeptic: That sounds promising, but how robust is the evidence? Have these effects been consistently observed across different cancer types?

Advocate: The preliminary data is encouraging, showing significant effects in glioblastoma and pancreatic cancer models. But, as with any research, further studies are needed to generalize these findings.

Skeptic: So, we're talking about a narrow application at this stage. What about potential side effects on normal cells?

Advocate: Another valid concern. Early trials indicate that normal cells, due to their lower glutamine dependence, are less affected. However, it's an area that requires careful monitoring.

Skeptic: I see. It seems we're at the forefront of understanding this mechanism, but there's a lot that remains to be clarified.

Advocate: Absolutely. The goal is to map out these points of contention, like you've helped highlight. It's a step towards refining this approach, making it more viable for therapeutic use.

Skeptic: Agreed. Let's keep the dialogue going as new data emerges. Science thrives on such constructive skepticism.

Advocate: Precisely. Only through rigorous questioning can we refine our understanding. Let's continue to explore this promising frontier.
```